SKYE Insider Trading
Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,910,712.67
Skye Bioscience Share Price & Price History
Current Price: $2.36
Price Change: ▲ Price Increase of +0.01 (0.43%)
As of 03/25/2025 05:00 PM ET
Skye Bioscience Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
11/18/2024 | Kaitlyn Arsenault | CFO | Sell | 43,206 | $4.99 | $215,597.94 | 166,342 | |
11/18/2024 | Paul A Grayson | Director | Sell | 86,244 | $4.99 | $430,357.56 | 259,701 | |
11/18/2024 | Punit Dhillon | CEO | Sell | 82,546 | $4.99 | $411,904.54 | 329,823 | |
11/18/2024 | Tuan Tu Diep | Insider | Sell | 19,489 | $4.99 | $97,250.11 | 82,259 | |
11/15/2024 | Kaitlyn Arsenault | CFO | Sell | 190 | $5.55 | $1,054.50 | 209,548 | |
11/15/2024 | Paul A Grayson | Director | Sell | 307 | $5.55 | $1,703.85 | 345,945 | |
11/15/2024 | Punit Dhillon | CEO | Sell | 364 | $5.55 | $2,020.20 | 412,369 | |
11/15/2024 | Tuan Tu Diep | Insider | Sell | 85 | $5.55 | $471.75 | 101,748 | |
9/13/2024 | Andrew J Schwab | Director | Sell | 13,837 | $6.06 | $83,852.22 | 66,277 | |
9/11/2024 | Andrew J Schwab | Director | Sell | 252,500 | $6.60 | $1,666,500.00 | 66,356 | |
Skye Bioscience Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
2/17/2025 | Squarepoint Ops LLC | 13,546 | $38K | 0.0% | N/A | 0.045% |  |
2/17/2025 | Two Sigma Advisers LP | 11,200 | $32K | 0.0% | N/A | 0.037% |  |
2/17/2025 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 326,241 | $0.92M | 0.0% | -5.3% | 1.075% |  |
2/17/2025 | Ensign Peak Advisors Inc | 767,287 | $2.17M | 0.0% | -14.7% | 2.529% |  |
2/17/2025 | Deutsche Bank AG | 40,835 | $0.12M | 0.0% | +365.0% | 0.135% |  |
2/17/2025 | Bridgeway Capital Management LLC | 72,000 | $0.20M | 0.0% | +26.3% | 0.237% |  |
2/17/2025 | Braidwell LP | 825,732 | $2.34M | 0.1% | N/A | 2.722% |  |
2/17/2025 | Baker BROS. Advisors LP | 1,450,638 | $4.11M | 0.0% | +1.1% | 4.781% |  |
2/17/2025 | Bank of America Corp DE | 39,257 | $0.11M | 0.0% | +37.4% | 0.129% |  |
2/17/2025 | BNP Paribas Financial Markets | 31,637 | $90K | 0.0% | -33.3% | 0.104% |  |
2/17/2025 | Alyeska Investment Group L.P. | 456,163 | $1.29M | 0.0% | -17.7% | 1.504% |  |
2/14/2025 | Jane Street Group LLC | 36,057 | $0.10M | 0.0% | +195.5% | 0.119% |  |
2/14/2025 | Schonfeld Strategic Advisors LLC | 1,422,741 | $4.03M | 0.0% | +48.3% | 4.689% |  |
2/14/2025 | AdvisorShares Investments LLC | 88,391 | $0.25M | 0.0% | -23.1% | 0.291% |  |
2/14/2025 | Northern Trust Corp | 135,712 | $0.38M | 0.0% | -3.7% | 0.447% |  |
2/14/2025 | Altium Capital Management LLC | 1,139,000 | $3.22M | 0.9% | -13.4% | 3.754% |  |
2/13/2025 | Barclays PLC | 69,620 | $0.20M | 0.0% | +20.3% | 0.229% |  |
2/13/2025 | Wells Fargo & Company MN | 11,199 | $32K | 0.0% | +49.0% | 0.037% |  |
2/12/2025 | Geode Capital Management LLC | 405,694 | $1.15M | 0.0% | +5.2% | 1.337% |  |
2/11/2025 | Virtu Financial LLC | 10,142 | $29K | 0.0% | N/A | 0.033% |  |
2/11/2025 | Platinum Investment Management Ltd. | 434,046 | $1.23M | 0.1% | -10.5% | 1.431% |  |
2/6/2025 | Charles Schwab Investment Management Inc. | 62,363 | $0.18M | 0.0% | +20.7% | 0.206% |  |
1/1/2025 | JPMorgan Chase & Co. | 11,362 | $44K | 0.0% | -24.1% | 0.037% |  |
11/19/2024 | Barclays PLC | 57,889 | $0.23M | 0.0% | +36.7% | 0.191% |  |
11/16/2024 | Geode Capital Management LLC | 385,793 | $1.51M | 0.0% | +4.2% | 1.272% |  |
11/15/2024 | Barclays PLC | 57,889 | $0.23M | 0.0% | +36.7% | 0.191% |  |
11/15/2024 | Jane Street Group LLC | 12,200 | $48K | 0.0% | N/A | 0.040% |  |
11/15/2024 | Sphera Funds Management LTD. | 1,563,522 | $6.11M | 1.0% | +20.4% | 5.153% |  |
11/15/2024 | State Street Corp | 354,205 | $1.39M | 0.0% | +7.0% | 1.167% |  |
11/15/2024 | Point72 Asset Management L.P. | 416,424 | $1.63M | 0.0% | -25.6% | 1.373% |  |
11/15/2024 | Baker BROS. Advisors LP | 1,434,634 | $5.61M | 0.1% | +186.9% | 4.729% |  |
11/13/2024 | BNP Paribas Financial Markets | 47,417 | $0.19M | 0.0% | +71.1% | 0.156% |  |
9/16/2024 | Point72 DIFC Ltd | 6,000 | $48K | 0.0% | N/A | 0.021% |  |
9/16/2024 | Cubist Systematic Strategies LLC | 3,762 | $30K | 0.0% | N/A | 0.013% |  |
9/16/2024 | Point72 Asia Singapore Pte. Ltd. | 27,768 | $0.22M | 0.0% | N/A | 0.099% |  |
8/19/2024 | Point72 Asset Management L.P. | 560,000 | $4.49M | 0.0% | N/A | 1.995% |  |
8/16/2024 | Perceptive Advisors LLC | 500,000 | $4.01M | 0.1% | N/A | 1.781% |  |
8/16/2024 | Driehaus Capital Management LLC | 650,758 | $5.21M | 0.0% | N/A | 2.319% |  |
8/15/2024 | CVI Holdings LLC | 679,739 | $5.45M | 4.9% | N/A | 2.422% |  |
8/15/2024 | Point72 Asia Singapore Pte. Ltd. | 27,768 | $0.22M | 0.0% | N/A | 0.099% |  |
8/14/2024 | Cubist Systematic Strategies LLC | 3,762 | $30K | 0.0% | N/A | 0.013% |  |
8/14/2024 | Point72 DIFC Ltd | 6,000 | $48K | 0.0% | N/A | 0.021% |  |
8/14/2024 | Logos Global Management LP | 1,301,518 | $10.43M | 0.8% | N/A | 4.637% |  |
8/8/2024 | AdvisorShares Investments LLC | 26,000 | $0.21M | 0.0% | N/A | 0.093% |  |
8/1/2024 | Rhumbline Advisers | 19,754 | $0.16M | 0.0% | N/A | 0.070% |  |
7/26/2024 | Bank of New York Mellon Corp | 58,778 | $0.47M | 0.0% | N/A | 0.209% |  |
Data available starting January 2016
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Read More on Skye Bioscience
Volume
154,600 shs
Average Volume
214,191 shs
Market Capitalization
$71.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.71
Who are the company insiders with the largest holdings of Skye Bioscience?
Who are the major institutional investors of Skye Bioscience?
Which institutional investors are selling Skye Bioscience stock?
In the last quarter, SKYE stock was sold by these institutional investors:
- Altium Capital Management LLC
- Ensign Peak Advisors Inc
- Alyeska Investment Group L.P.
- Platinum Investment Management Ltd.
- AdvisorShares Investments LLC
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
- BNP Paribas Financial Markets
- Citadel Advisors LLC
During the previous year, company insiders that have sold Skye Bioscience company stock include:
- Punit Dhillon (CEO)
- Paul A Grayson (Director)
- Kaitlyn Arsenault (CFO)
- Tuan Tu Diep (Insider)
- Andrew J Schwab (Director)
Learn More investors selling Skye Bioscience stock.
Which institutional investors are buying Skye Bioscience stock?
In the previous quarter, SKYE stock was acquired by institutional investors including:
- Braidwell LP
- Schonfeld Strategic Advisors LLC
- Deutsche Bank AG
- Jane Street Group LLC
- Geode Capital Management LLC
- Baker BROS. Advisors LP
- Bridgeway Capital Management LLC
- Squarepoint Ops LLC